EMG
CLSD

Ellington Management Group’s Clearside Biomedical CLSD Stock Holding History

Ellington Management Group’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-867
Closed -$139K – 525
2018
Q2 		$139K Sell
867
-1,233
-59% -$208K 0.01% 444
2018
Q1 		$338K Buy
+2,100
New +$256K 0.02% 544
2017
Q1 		– Sell
-1,513
Closed -$203K – 710
2016
Q4 		$203K Buy
+1,513
New +$380K 0.03% 434

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Ellington Management Group's CLSD Position: Q3 2018 in Review

Ellington Management Group sold out of Clearside Biomedical (CLSD) in Q3 2018, closing a stake of 867 shares — an estimated $139K sold.

Ellington Management Group first reported a position in CLSD in Q4 2016 and held it in 3 quarters. The position peaked at $338K in Q1 2018. 89 funds tracked by Wall St. Rank hold CLSD as of Q3 2018.

  • Ellington Management Group reported no remaining Clearside Biomedical position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 867 Clearside Biomedical shares in Q3 2018, an estimated $139K.
  • Ellington Management Group first reported a position in Clearside Biomedical in Q4 2016 and held it in 3 quarters.
  • Ellington Management Group's Clearside Biomedical position peaked at $338K in Q1 2018.
  • 89 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.